Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Weekes
Colin D
CD
University of Colorado Cancer Center, 12801 E 17th Avenue, RC-1 South, Rm 8123, MS 8117, Aurora, CO 80045, USA. colin.weekes@ucdenver.edu
Nallapareddy
Sujatha
S
Rudek
Michelle A
MA
Norris-Kirby
Alexis
A
Laheru
Daniel
D
Jimeno
Antonio
A
Donehower
Ross C
RC
Murphy
Kathleen M
KM
Hidalgo
Manuel
M
Baker
Sharyn D
SD
Messersmith
Wells A
WA
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069287:Capecitabine; D003710:Demography; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004742:Enhancer Elements, Genetic / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005838:Genotype; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000235:genetics*; D016896:Treatment Outcome; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000069287:Capecitabine; D013940:Thymidylate Synthase; D005472:Fluorouracil; D000093542:Gemcitabine